Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Relying On ICD Boom To Weather Slowdown In Pacer Sales

This article was originally published in The Gray Sheet

Executive Summary

St. Jude continues to benefit from the rapidly expanding ICD market, although pacemaker sales are constrained by competition from cardiac resynchronization therapy (CRT) devices for congestive heart failure

You may also be interested in...



Guidant Surveys Resynch Pool: Doc Loyalty, Sales Presence Will Rule The Day

Cardiac resynchronization defibrillator procedures, by their inherent complexity, will foster loyalty to a single manufacturer's CRT-D devices, Guidant President and CEO Ron Dollens asserted at JPMorgan's annual healthcare conference in San Francisco Jan. 12

Guidant Surveys Resynch Pool: Doc Loyalty, Sales Presence Will Rule The Day

Cardiac resynchronization defibrillator procedures, by their inherent complexity, will foster loyalty to a single manufacturer's CRT-D devices, Guidant President and CEO Ron Dollens asserted at JPMorgan's annual healthcare conference in San Francisco Jan. 12

St. Jude Resynchronization ICD Enrollment Trimmed By 150 Patients

St. Jude continues to project that its Epic HF resynchronization ICD will not reach the U.S. market until early 2004, despite FDA permission to reduce the required sample size of the pivotal RHYTHM study

Related Content

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel